7007-92-3

Usage

Uses

Used in Pharmaceutical Industry:
Cetohexazine is used as an antihistamine for treating allergies and allergic reactions by blocking the effects of histamine, a substance in the body that causes these symptoms.
Cetohexazine is also used as a sedative for relieving symptoms of anxiety and tension by decreasing the activity of the central nervous system, leading to a calming and sedating effect.
It is available in the form of oral tablets and should be taken as directed by a healthcare professional to ensure safe and effective use. Common side effects may include drowsiness, dizziness, and dry mouth, and it is important to avoid alcohol and certain medications while taking cetohexazine.

InChI:InChI=1/C6H8N2O/c1-4-3-5(2)7-8-6(4)9/h3H,1-2H3,(H,8,9)

Upstream product

• 35504-82-6 2-methyl-4-oxo-pent-2c-enoic acid 
• 50-00-0 formaldehyd 
• 1027102-66-4 4-diethoxyphosphoryl-6-methylpyridazin-3(2H)-one 
• 6641-83-4 2-methyl-4-oxopentanoic acid 
• 23227-96-5 4,5-dihydro-4,6-dimethylpyridazin-3(2H)-one 
• 81416-97-9 2-Hydroxy-4-oxo-2-methyl-pentansaeure 

Downstream Products

• 17258-26-3 3-chloro-4,6-dimethylpyridazine 
• 118269-99-1 (4,6-Dimethyl-pyridazin-3-yl)-(2-morpholin-4-yl-ethyl)-amine; hydrochloride 

Relevant academic research and scientific papers

New, simple and versatile synthesis of 4,6-disubstituted pyridazin-3(2H)-ones

A simple, two-step synthesis of 4,6-disubstituted pyridazin-3(2H)-ones starting from 2-diethoxyphosphoryl-4-oxoalkanoates and hydrazines is described. The intermediate 4-diethoxyphosphoryl-4,5-dihydropyridazin-3(2H)-ones obtained in this way are used in a

Development of a novel therapeutic suppressor of brain proinflammatory cytokine up-regulation that attenuates synaptic dysfunction and behavioral deficits

We report the development of a novel, aqueous-soluble, safe, small molecule, experimental therapeutic that suppresses injury-induced, proinflammatory cytokine increases in the brain, with resultant attenuation of synaptic protein biomarker loss and improvement in hippocampus-dependent behavioral deficits. A GMP production scheme for the active pharmaceutical ingredient, compound 17, is presented. The development and large-scale availability of this novel compound allow exploration of new, potentially disease-modifying, therapeutic approaches to CNS disorders.

3-Aminopyridazine derivatives with atypical antidepressant, serotonergic, and dopaminergic activities

Minaprine [3[(β-morpholinoethyl)amino]4-methyl-6-phenylpyridazine dihydrochloride] is active in most animal models of depression and exhibits in vivo a dual dopaminomimetic and serotoninomimetic activity profile. In an attempt to dissociate these two effe